ES2108425T3 - Analogos de atp sustituidos con n-alquilo-2. - Google Patents

Analogos de atp sustituidos con n-alquilo-2.

Info

Publication number
ES2108425T3
ES2108425T3 ES94905810T ES94905810T ES2108425T3 ES 2108425 T3 ES2108425 T3 ES 2108425T3 ES 94905810 T ES94905810 T ES 94905810T ES 94905810 T ES94905810 T ES 94905810T ES 2108425 T3 ES2108425 T3 ES 2108425T3
Authority
ES
Spain
Prior art keywords
sup
alkyl
sub
halogen
atp analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94905810T
Other languages
English (en)
Inventor
Anthony Howard Ingall
Peter Alan Cage
Nicholas David Kindon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astra Pharmaceuticals Ltd
Astra USA Inc
Original Assignee
Astra Pharmaceuticals Ltd
Astra Pharmaceutical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939302636A external-priority patent/GB9302636D0/en
Priority claimed from GB939325712A external-priority patent/GB9325712D0/en
Application filed by Astra Pharmaceuticals Ltd, Astra Pharmaceutical Products Inc filed Critical Astra Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2108425T3 publication Critical patent/ES2108425T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

HAN SIDO DESCUBIERTOS COMPUESTOS DE LA FORMULA (I) EN LA QUE R{SUP,1} Y R{SUP,2} REPRESENTAN INDEPENDIENTEMENTE HIDROGENO O HALOGENO, R{SUP,3} Y R{SUP,4} REPRESENTAN INDEPENDIENTEMENTE FENILO, O ALQUILO C{SUB,1-6} OPCIONALMENTE SUSTITUIDO POR UNO O MAS SUSTITUYENTES SELECCIONADOS ENTRE OR{SUP,5}, ALQUILTIO C{SUB,1-6}, NR{SUP,6}R{SUP,7}, FENILO, COOR{SUP,8} Y HALOGENO, R{SUP,5}, R{SUP,6}, R{SUP,7} Y R{SUP,8} INDEPENDIENTEMENTE REPRESENTAN HIDROGENO O ALQUILO C{SUB,1-6}, Y X REPRESENTA UNA MITAD ACIDICA Y SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. TAMBIEN SE DESCRIBE UN PROCESO PARA SU PRODUCCION Y COMPOSICIONES FARMACEUTICAS Y METODOS DE TRATAMIENTO QUE IMPLICAN SU USO.
ES94905810T 1993-02-10 1994-02-08 Analogos de atp sustituidos con n-alquilo-2. Expired - Lifetime ES2108425T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939302636A GB9302636D0 (en) 1993-02-10 1993-02-10 Compounds
GB939325712A GB9325712D0 (en) 1993-12-16 1993-12-16 Compounds

Publications (1)

Publication Number Publication Date
ES2108425T3 true ES2108425T3 (es) 1997-12-16

Family

ID=26302434

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94905810T Expired - Lifetime ES2108425T3 (es) 1993-02-10 1994-02-08 Analogos de atp sustituidos con n-alquilo-2.

Country Status (26)

Country Link
US (2) US5721219A (es)
EP (1) EP0683789B1 (es)
JP (1) JP3083156B2 (es)
KR (1) KR100315612B1 (es)
CN (1) CN1042430C (es)
AT (1) ATE159950T1 (es)
AU (1) AU679721B2 (es)
CA (1) CA2155673C (es)
CZ (1) CZ286050B6 (es)
DE (1) DE69406649T2 (es)
DK (1) DK0683789T3 (es)
ES (1) ES2108425T3 (es)
FI (1) FI110687B (es)
GR (1) GR3025995T3 (es)
HK (1) HK1002936A1 (es)
HU (1) HU221501B (es)
IL (1) IL108602A (es)
NO (1) NO305209B1 (es)
NZ (1) NZ261159A (es)
PL (1) PL175623B1 (es)
RU (1) RU2136693C1 (es)
SG (1) SG47943A1 (es)
SK (1) SK281309B6 (es)
TW (1) TW326045B (es)
UA (1) UA54366C2 (es)
WO (1) WO1994018216A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281309B6 (sk) * 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov
WO1998018430A2 (en) * 1996-10-30 1998-05-07 The University Of North Carolina At Chapel Hill P2y receptor antagonists
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
AU2003257524B2 (en) * 1997-07-11 2006-04-06 Astrazeneca Ab New formulation
FI104901B (fi) * 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US6750340B2 (en) * 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US8586781B2 (en) 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6303774B1 (en) 1999-08-20 2001-10-16 Sri International Nucleoside pyrophosphate and triphosphate analogs and related compounds
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US7285658B2 (en) * 2002-02-28 2007-10-23 Biota, Inc. Nucleotide mimics and their prodrugs
US20050192245A1 (en) * 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
CN1681533A (zh) * 2002-07-18 2005-10-12 三共株式会社 用于治疗动脉硬化的药用组合物
US8222229B2 (en) 2002-11-21 2012-07-17 Kowa Co., Ltd. Peritoneal dialysis method
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
EP1604669A1 (en) * 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) * 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) * 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
BR112012011298B1 (pt) * 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2669292B1 (en) * 2011-01-26 2017-03-29 Beijing KBD Pharmaceuticals Co., Ltd. Ribofuranosyl purine compounds for treating diseases associated with platelet aggregation
WO2012109406A1 (en) 2011-02-09 2012-08-16 The Medicines Company Methods for treating pulmonary hypertension
CA2843885C (en) 2011-08-01 2020-03-10 Mbc Pharma, Inc. Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
AU2013381855B2 (en) 2013-03-09 2018-08-02 Chiesi Farmaceutici S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN104447927A (zh) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 坎格雷洛一水合物晶体及其制备方法
CN104447928A (zh) * 2013-09-13 2015-03-25 天津市汉康医药生物技术有限公司 坎格雷洛二水化合物
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
CN105273025B (zh) * 2014-07-22 2019-07-26 上海医药工业研究院 一种制备坎格雷洛的中间体及其制备方法和应用
MA41326A (fr) 2015-01-14 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
WO2017076266A1 (zh) * 2015-11-06 2017-05-11 江苏恒瑞医药股份有限公司 制备坎格雷洛中间体的方法
CN107973798B (zh) * 2016-10-25 2020-04-24 上海医药工业研究院 2-[(3,3,3-三氟丙基)硫代]-6-氨基-9h-嘌呤及制法
CN107973832B (zh) * 2016-10-25 2021-11-12 上海医药工业研究院 6-n-[2-(甲硫基)乙基]-2-[(3，3，3-三氟丙基)硫代]腺苷的制法
CN106674322B (zh) * 2016-12-07 2019-04-16 上海博志研新药物技术有限公司 一种坎格雷洛中间体的纯化方法
WO2018185715A1 (en) * 2017-04-06 2018-10-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of n6-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-5'-adenylic acid, monoanhydride with (dichloromethylene) bisphosphonic acid and its pharmaceutically acceptable salts
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY
US11279724B2 (en) 2017-11-10 2022-03-22 Olon S.P.A. Efficient method for the preparation of Cangrelor
CN109912674A (zh) * 2017-12-12 2019-06-21 亚宝药业集团股份有限公司 一种坎格雷洛四钠盐的制备方法
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
US20190241606A1 (en) * 2018-02-05 2019-08-08 Scinopharm Taiwan, Ltd. Process for preparation of cangrelor tetrasodium and intermediate therefor
CN108033983B (zh) * 2018-02-09 2021-06-08 盐城锦明药业有限公司 一种2‐(3,3,3‐三氟丙基)硫代腺苷的合成方法
EP4289435A1 (en) 2022-06-07 2023-12-13 Université de Liège N-alkyl-2-substituted atp analogues for use as antibacterial agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU764326A1 (ru) * 1977-11-16 1982-09-23 Ордена Ленина Институт Химической Физики Ан Ссср Способ получени спин-меченого производного аденозинтрифосфата
US5049550A (en) * 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
WO1990011080A1 (en) * 1989-03-24 1990-10-04 Daiichi Pharmaceutical Co., Ltd. Drug for improving brain function
GB9107236D0 (en) 1991-04-06 1991-05-22 Fisons Plc Compounds
DE69204717T2 (de) * 1991-04-06 1996-04-25 Astra Pharmaceuticals Limited, Kings Langley, Herts ATP-Analogen.
SK281309B6 (sk) * 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov

Also Published As

Publication number Publication date
FI953794L (fi) 1995-08-10
PL175623B1 (pl) 1999-01-29
JPH08506335A (ja) 1996-07-09
CZ203295A3 (en) 1995-12-13
NO953126D0 (no) 1995-08-09
EP0683789B1 (en) 1997-11-05
IL108602A0 (en) 1994-05-30
KR100315612B1 (ko) 2002-06-20
GR3025995T3 (en) 1998-04-30
NO953126L (no) 1995-09-28
NZ261159A (en) 1997-06-24
HU221501B (en) 2002-10-28
IL108602A (en) 1999-12-22
SG47943A1 (en) 1998-04-17
ATE159950T1 (de) 1997-11-15
NO305209B1 (no) 1999-04-19
US5955447A (en) 1999-09-21
AU679721B2 (en) 1997-07-10
CZ286050B6 (cs) 1999-12-15
CA2155673A1 (en) 1994-08-18
DK0683789T3 (da) 1998-02-09
US5721219A (en) 1998-02-24
HK1002936A1 (en) 1998-09-25
HUT72464A (en) 1996-04-29
UA54366C2 (uk) 2003-03-17
CA2155673C (en) 2004-08-17
SK99495A3 (en) 1996-02-07
CN1042430C (zh) 1999-03-10
TW326045B (en) 1998-02-01
SK281309B6 (sk) 2001-02-12
RU2136693C1 (ru) 1999-09-10
DE69406649D1 (de) 1997-12-11
FI953794A0 (fi) 1995-08-10
DE69406649T2 (de) 1998-03-05
AU5977094A (en) 1994-08-29
JP3083156B2 (ja) 2000-09-04
WO1994018216A1 (en) 1994-08-18
FI110687B (fi) 2003-03-14
EP0683789A1 (en) 1995-11-29
PL310160A1 (en) 1995-11-27
CN1119869A (zh) 1996-04-03

Similar Documents

Publication Publication Date Title
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
ES2072627T3 (es) Derivados de piridina y n-oxido de piridina de diarilmetilpiperidinas o piperazinas, composiciones y uso de las mismas.
ES2067248T3 (es) Derivados de indol como agentes antialergicos y antiinflamatorios.
MX9300786A (es) Compuestos hipolipidaemicos.
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ES2062395T3 (es) Nuevos compuestos de bencimidazol y su uso.
ES8505681A1 (es) Procedimiento para preparar n2-acil-9-(1, 3-dihidroxi-2-propoximetil)-guaninas y sus sales farmaceuticamente aceptables
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
ES2118457T3 (es) Derivados de piridina, composiciones farmaceuticas que comprenden los mismos, el uso de los mismos para la fabricacion de medicamentos que tienen valor terapeutico o preventivo, y un proceso para preparar los mismos.
ES2058292T3 (es) Derivados de indol.
ES2152938T3 (es) 1(2h)-isoquinolinas sustituidas antiarritmicas y cardioprotectoras, procedimiento para su produccion, medicamento que las contiene y su uso para la produccion de un medicamento para combatir fallos cardiacos.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2062215T3 (es) Derivados aminoalcoxibencenicos sustituidos.
DK519788A (da) 1-(benzylpiperidino)propan-2-ol-derivater og fremgangsmaade til fremstilling deraf, deres anvendelse som antimikrobielle midler samt produkter indeholdende dem
ES452200A1 (es) Un procedimiento para la preparacion de nuevos derivados de pipendina.
ES2043863T3 (es) Procedimiento para preparar derivados de la 1,2,5,6-tetrahidropiridina.
NO157643C (no) Anvendelse av sitronsyre for aa forhindre nedbrytning av farmasoeytisk taalbare syreaddisjonssalter av tienopyridinderivater.
ES2153019T3 (es) Derivados de benzo-dioxano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2039292T3 (es) Derivados de piranobenzoxadiazol, preparacion de los mismos, utilizacion y compuestos que los comprenden.
DK408083D0 (da) Isoquinilinderivater, deres fremstilling og anvendelse
AU534470B2 (en) Paromomycin derivatives
FR2630110B1 (fr) Nouveaux derives heteroarotinoides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2032838T3 (es) Un procedimiento para preparar derivados tetrahidropirido (1,2-a)indol.
ES2189108T3 (es) Nuevas oxazinas dissustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 683789

Country of ref document: ES